In summary, we have demonstrated, for the first time, that decytabine, DNMT inhibitor, exerted powerful synergistic interaction with oxaliplatin and 5-FU, inhibiting the survival of CRC cells in vitro. This evidence concerns the gene DNMT1 and colorectal carcinoma.